The U.S. Food and Drug Administration (FDA) on July 28 approved Sanofi’s Adlyxin (lixisenatide) to improve glycemic control in patients with type 2 diabetes. The drug is a glucagon-like peptide-1 receptor agonist and is administered once daily via injection.

According to the FDA, lixisenatide “should not be used to treat people with type 1 diabetes or patients with diabetic ketoacidosis.”

Read the FDA announcement.

Clinical Topics: Diabetes and Cardiometabolic Disease

Keywords: Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Peptides, United States Food and Drug Administration, Metabolic Syndrome

< Back to Listings